Roflumilast Topical

Indications

• treatment of ezcema (FDA-approved)
• treatment of plaque psoriasis
• treatment of seborrheic dermatitis

Dosage

• 0.15% cream for treatment of eczema
• 0.3% cream for treatment of plaque psoriasis
• 0.3% foam for treatment of seborrheic dermatitis

Adverse effects

• headache (2.9%)
• nausea (1.9%), vomiting (1.5%)
• diarrhea (1.5%)
• application site pain (1.5%)

Mechanism of action

• see roflumilast

More general terms

• roflumilast (Daliresp)
• topical agent